Pharmacological Advances in Inflammatory Bowel Disease: Mechanisms, Biomarkers, and Therapeutic Strategies

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic, relapsing inflammatory disorder of the gastrointestinal tract that continues to pose major clinical challenges worldwide. Despite advances in immunomodulatory therapies and biologics, many patients experience limited efficacy, loss of response over time, or significant adverse effects, highlighting the urgent need for novel therapeutic approaches and precision medicine strategies.

Emerging research has highlighted the complex interplay of immune dysregulation, gut microbiota alterations, epithelial barrier dysfunction, and genetic susceptibility in the pathogenesis of IBD. Recent pharmacological studies have identified new pathways of interest, including cytokine signaling, JAK/STAT modulation, integrin and sphingosine-1-phosphate receptor antagonism, and microbial-derived metabolites as potential therapeutic targets. In addition, natural products, probiotics, and systems biology approaches are being explored to complement or enhance existing therapies.

This Research Topic aims to integrate mechanistic insights with translational pharmacology to drive forward innovative strategies for IBD management. We welcome contributions that explore novel drug targets, pharmacokinetics, biomarkers of treatment response, and strategies to optimize bioavailability and reduce toxicity. Studies focusing on drug repurposing, combination therapies, and patient-specific approaches are also encouraged.

Areas of interest include, but are not limited to:

• Molecular mechanisms underlying gut inflammation and epithelial barrier dysfunction
• Pharmacological modulation of cytokine, JAK/STAT, and S1P pathways in IBD
• Role of gut microbiota and microbial metabolites in therapeutic intervention
• Development of biomarkers for disease activity and drug response
• Natural compounds and probiotics as adjunctive therapies
• Preclinical and clinical evaluation of emerging pharmacological agents
• Drug delivery innovations to enhance bioavailability and tissue targeting
• Translational strategies toward precision medicine in IBD

We invite original research, reviews, and translational studies that contribute to the discovery of novel pharmacological strategies and mechanistic understanding, with the ultimate goal of improving outcomes for patients living with IBD.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Clinical Trial
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Clinical Trial
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: Inflammatory bowel disease pharmacology, JAK/STAT and S1P pathway modulation, Gut microbiota–derived therapeutics, Biomarkers and precision medicine in IBD, Drug delivery and bioavailability optimization

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.